NeoGenomics Engager | In-Person Event


Tuesday 25th October, 2022 | Barcelona | 6.30pm CET

Free-to-Attend & In-Person Only Event

Barcelona, Spain - Venue: El Xalet de Montjuïc

From Idea to Commercialization: Advancing the Biomarker
Development Journey

The NeoGenomics Engager will take biopharma Directors, Heads & VPs working in the translational and precision oncology space on a deep dive into the new, emerging and transformative opportunities IHC and mIF biomarker assays hold for the future of cancer care.

At a crucial time for the precision medicine industry, this is your chance to engage with expert leaders and discuss the different strategies that will allow you to speed up the development process and move your candidate successfully to the clinic.

Hear the latest insights and case studies in this exclusive and invitation-only event, providing you with the best practices when advancing biomarkers from early stage through development, all the way to commercialization. Join us to assess the role of protein biomarkers in patient enrolment and stratification, and how they can facilitate quicker and more informed treatment decision-making in precision drug development.

With an insightful panel discussion among key opinion leaders followed by complimentary appetizers and drinks, this is an opportunity not to be missed!

Please Note: This event is taking place in-person only (Barcelona, Spain) and online attendance will not be available.

Your Expert Speakers:

More speakers TBC!

Reserve Your Free Seat By Filling Out the Form Below:

Please Note: This event is taking place in-person only (Barcelona, Spain) and online attendance will not be available.

Having trouble registering? Email:

*Attendance is subject to final approval from the event organizers


El Xalet de Montjuïc

Av. Miramar 31, 08038 BCN

Check Out Their Website Here

Agenda: From Idea to Commercialization: Advancing the Biomarker Development Journey

Tuesday 25th October, 2022 | Barcelona, Spain | 6.30pm CET

6:30 pm Welcome Reception & Registration

7:00 pm Opening Remarks

7:05 pm Presentation: Perivascular Macrophages: Key Suppressors of Antitumour Treatments

  • Claire Lewis Professor of Molecular & Cellular Pathology Research Director
    Weston Park Cancer Centre,
    Visiting Professor
    Leiden University,
    Department of Oncology & Metabolism, University of Sheffield


• Perivascular macrophages can limit the efficacy of various anti-cancer treatments
• MultiOmyx analysis was used to define phenotype and functions of these macrophages in human breast tumours
• The study highlighted marked changes in the perivascular niche during treatment

7:25 pm Panel Discussion & Q&A: Advancing the Biomarker Journey with CDx Development

  • Scott Reid Vice President, Alliances & Companion Diagnostics, NeoGenomics


– Discussing proven strategies for early phase development of prototype CDx in clinical trials

– Discovering how to approach new technologies for CDx development including multiplex IHC, flow cytometry and gene signatures

– Addressing different ways to ensure availability of novel CDx assays following drug approval

7:50 pm Networking Session


This is an informal and exclusive networking opportunity for you to engage with biopharma and NeoGenomic leaders to discuss how to advance Precision Medicine in oncology

8:30 pm End of NeoGenomics Engager

About NeoGenomics:


NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialty pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery across our global laboratory sites (US, EU, APAC & China) from biomarker discovery through CDx validation and commercialization.